Table 1. Clinical Characteristics and Genetic Background of Participants by Study Group.

	G+/LVH+(n=81)	G+/LVH-(n=55)	Control (n=42)	3- Group P-Value	G+/LVH+ vs G+/LVH-P-value	G+/LVH+ vs Control P-value	G+/LVH- vs Control P-value
Age at baseline, yrs	26.9 (14)	20.4 (10)	17.5 (8)	< 0.001	0.003	<0.0001	0.12
Female, n (%)	28 (35%)	30 (55%)	24 (57%)	0.019	0.02	0.02	0.80
Race, n (%)				0.122	0.11	0.42	0.08
White	75 (93%)	55 (100%)	39 (93%)
Black or African American	5 (6%)	0 (0%)	1 (2%)
Asian	1 (1%)	0 (0%)	1 (2%)
More than one race	0 (0%)	0 (0%)	1 (2%)
Body Surface Area (kg/m2)	1.83 (0.41)	1.69 (0.32)	1.61 (0.40)	0.006	0.02	0.005	0.33
Height, cm	168.5 (17.8)	162.2 (14.4)	159.6 (18.0)	0.012	0.03	0.01	0.42
Weight, kg	72.3 (24.1)	63.2 (18.3)	59.5 (22.5)	0.005	0.01	0.005	0.38
Systolic blood pressure, mmHg	115 (15)	113 (12)	113 (13)	0.724	0.50	0.54	0.99
Diastolic blood pressure, mmHg	68 (9)	68 (9)	66 (10)	0.510	0.80	0.34	0.28
NYHA Class, n(%)
Class I	67 (83%)	55 (100%)	42 (100%)
Class II	10 (12%)	0 (0%)	0 (0%)
Class III	2 (2%)	0 (0%)	0 (0%)
Class IV	2 (2%)	0 (0%)	0 (0%)
Medication Use, n (%)
Amiodarone	3 (4%)	0 (0%)	0 (0%)
β-blockers	28 (35%)	1 (2%)	0 (0%)
Calcium channel blockers	9 (11%)	1 (2%)	0 (0%)
Disopyramide	1 (1%)	0 (0%)	0 (0%)
Coumadin/warfarin	3 (4%)	0 (0%)	0 (0%)
No medications	32 (40%)	34 (62%)	32 (76%)
Genetic Background, n (%)
MYH7	26 (32%)a	22 (40%)
MYBPC3	44 (54%)b	29 (53%)e
TNNT2	7 (9%)c	1 (2%)
TNNI3	1 (1%)	0
MYL2	1 (1%)	0
MYL3	2 (3%)d	2 (3%)
ACTC	0	1 (2%)

Values are reported as mean (SD) or n (%)

P values <0.017 are considered statistically significant, applying post hoc Bonferroni correction.

^aOne patient also had a secondary MYH7 mutation

^bOne patient also had a TNNI3 mutation and one had a secondary MYBPC3 mutation

^cOne patient also had a secondary MYBPC3 mutation

^dBoth patients also had a secondary MYBPC3 mutation

^eOne patient also had a secondary MYBPC3 mutation